Advertisement

Investigational Herpes Drug Limits Viral Shedding in Phase II Trial — Physician’s First Watch

Medical News |
January 16, 2014

Investigational Herpes Drug Limits Viral Shedding in Phase II Trial

By Kelly Young

Pritelivir, the first in a new class of drugs (a helicase-primase inhibitor) for herpes simplex virus, effectively suppressed viral shedding and development of genital lesions in an industry-conducted, phase II trial published in the New England Journal of Medicine.

Roughly 150 patients seropositive for HSV-2 and clinically symptomatic were randomized to receive pritelivir or placebo for 28 days. Participants provided daily genital swabs. The primary outcome — the number of days of viral shedding — was significantly lower in the higher-dose treatment groups (16.6% for placebo vs. 2.1% for 75 mg daily and 5.3% for 400 mg weekly). When breakthrough shedding occurred, pritelivir use was associated with fewer DNA copies of the virus, compared with placebo.

Last May, the FDA placed clinical development of pritelivir on hold after studies in monkeys found dermal and hematologic toxicity. The authors say the current study did not show increased adverse events.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement